Skip to main content

Table 2 Some major clinical trials targeting cancer vasculature

From: Targeting the tumor stroma for cancer therapy

Target

Drug

Combination

Condition

Phase

Status

Trial number

VEGF/VEGFR

Bevacizumab

No

Solid tumors

IV

Completed

NCT01588184

 

Bevacizumab

Chemotherapies

Ovarian cancer

III

Active, not recruiting

NCT00565851

 

Bevacizumab

Erlotinib

Lung cancer

II

Completed

NCT01562028

 

Bevacizumab

Erlotinib

Hepatocellular Carcinoma

II

Completed

NCT01180959

 

Bevacizumab

Niraparib

Ovarian Cancer

I/II

Completed

NCT02354131

 

Olaparib

Chemotherapies

Ovarian Cancer

III

Active, not recruiting

NCT02477644

 

Olaparib

Enzalutamide, abiraterone acetate

Prostate Cancer

III

Active, not recruiting

NCT02987543

 

Bevacizumab

Osimertinib

Lung Cancer

I/II

Completed

NCT02803203

 

Bevacizumab

Osimertinib

Lung Cancer

III

Recruiting

NCT04181060

 

Ramucirumab

Erlotinib, Gefitinib, Osimertinib

Metastatic NSCLC

III

Active, not recruiting

NCT02411448

 

Ramucirumab

Paclitaxel

Gastric Adenocarcinoma

III

Completed

NCT01170663

 

Ramucirumab

No

Gastric Cancer and Adenocarcinoma

III

Completed

NCT00917384

 

Ramucirumab

No

Hepatocellular Carcinoma

III

Completed

NCT01140347

 

Ramucirumab

No

Hepatocellular Carcinoma

III

Completed

NCT02435433

 

Ramucirumab

No

Hepatocellular Carcinoma

III

Completed

NCT02435433

 

Aflibercept

FOLFIRI

Metastatic Colorectal Cancer

III

Completed

NCT00561470

 

Aflibercept

Levofolinate, Irinotecan, 5-FU

Metastatic Colorectal Cancer

II

Completed

NCT01882868

 

Aflibercept

Capecitabine

Metastatic Colorectal Cancer

I/II

Completed

NCT01661972

TKI

Sorafenib

No

Hepatocellular Carcinoma

III

Completed

NCT00692770

 

Sunitinib

AGS-003

Kidney Cancer

II

Completed

NCT00678119

 

Sunitinib

Nivolumab, Pazopanib, Ipilimumab

Renal Cell Carcinoma

I

Completed

NCT01472081

 

Pazopanib

No

Ovarian Cancer

I/II

Completed

NCT01238770

 

Pazopanib

No

Renal Cell Carcinoma

IV

Completed

NCT01521715

 

Pazopanib

Paclitaxel

Ovarian Cancer

II

Completed

NCT01644825

 

Pazopanib

GSK1120212

Solid Tumors, Thyroid Cancer

I

Completed

NCT01438554

ANG-VEGF

Vanucizumab

Atezolizumab

Solid Tumors

I

Completed

NCT01688206

 

Vanucizumab

Bevacizumab, Selicrelumab

Solid Tumors

I

Completed

NCT02665416

Plus immunotherapy

Bevacizumab

Nivolumab, Rucaparib

Peritoneal Cancer,Ovarian Cancer, Fallopian Tube Cancer

II

Recruiting

NCT02873962

 

Bevacizumab

Nivolumab and chemotherapies

Non-small Cell Lung Cancer

I

Completed

NCT01454102

 

Bevacizumab

Pembrolizumab

Clear Cell Renal Carcinoma

I/II

Completed

NCT02348008

 

Bevacizumab

Pembrolizumab

Glioblastoma

II

Completed

NCT02337491

 

Bevacizumab

Pembrolizumab

Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

II

Completed

NCT02853318

 

Bevacizumab

Durvalumab

Glioblastoma

II

Completed

NCT02336165

 

Bevacizumab

Durvalumab

Metastatic Breast Cancer

I

Completed

NCT02802098.

 

Bevacizumab

Tremelimumab

Colorectal Cancer With Liver Metastases

I

Active, not recruiting

NCT02754856

 

Vanucizumab

Atezolizumab

Metastatic Solid Tumors

I

Completed

NCT01688206